US20090291020A1 - Soft contact lens solution containing hyaluronic acid - Google Patents
Soft contact lens solution containing hyaluronic acid Download PDFInfo
- Publication number
- US20090291020A1 US20090291020A1 US12/512,521 US51252109A US2009291020A1 US 20090291020 A1 US20090291020 A1 US 20090291020A1 US 51252109 A US51252109 A US 51252109A US 2009291020 A1 US2009291020 A1 US 2009291020A1
- Authority
- US
- United States
- Prior art keywords
- contact lens
- solution
- soft contact
- eye
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
Definitions
- the current invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and/or eye-care.
- the invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses as well as contact lenses impregnated with the composition.
- contact lens wearers may need extra protection for their eyes. It could be useful to the eyes to dispense extra nutrition, such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage.
- extra nutrition such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage.
- eye healthcare several products are known to assist in the accelerated recovery of the soundness of the cornea. These products, however, usually have to be administered (dripped in or applied onto the eye) separately or have to be swallowed by the user.
- a method for the production of contact lenses for the treatment and/or care and/or protection of the eye may comprise the impregnation of contact lenses in a solution which comprises one or more suitable components for the treatment and/or care and/or protection of the eye.
- composition for the treatment and/or care and/or protection of the eye may comprise at least one suitable component for the treatment and/or care and/or protection of the eye.
- a contact lens for treatment and/or care and/or protection of the eye may be impregnated with a composition comprising at least one suitable component for the treatment and/or care and/or protection of the eye.
- the current invention therefore provides a method for the manufacture of contact lenses for the treatment and/or care and/or protection of the eyes, comprising the impregnation of contact lenses in a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes.
- a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes.
- the current invention provides a composition for the impregnation of contact lenses for the treatment and/or care and/or protection of the eyes, comprising compounds suitable for eye treatment or care or protection.
- the current invention offers various types of compounds dependent on the type of treatment, care or protection required.
- these compositions can be combined with the compounds usually used for disinfecting, cleaning, insertion, moisturizing, rinsing or storing of contact lenses, so that the user need not add these compounds separately.
- Compounds that can be applied are: for instance dexpanthenol, pantothenic acid, hyaluron acid, retinol (Vitamin A) and retinyl derivatives, carotene, thiamine (Vitamin B1), riboflavine (Vitamin B2), pyridoxine (Vitamin B6), nicotinic acid, nicotine acidamin, biotine (Vitamin B7), niacinamide and niacine (vitamin ⁇ B3), ascorbic acid (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatin, taurin, serine protease and other enzymes, propamidines, Vitamin D and its derivatives such as calciferol, Vitamin K
- Products used for maintenance and storage of contact lenses like cleaning products and disinfecting solutions, and sprays, so-called all-in-one solutions, storage liquids and rinsing liquids, insertion solutions and moisturizers, neutralizers in either liquid or tablet form, gels, coatings and tablets which either make or assist in making contact lens solutions or make solutions come into being or are used for or in such solutions.
- the composition can therefore appear in various forms, such as a solution, spray or tablet which after dissolution makes a solution.
- Compounds intended for the care of contact lenses may also be part of a tablet which is combined with a solution that contains the care, treatment or protection agent or the reverse. Obviously both could also be included in one tablet or in separate tablets. Even so compounds can be included in a solution that is to be mixed with a solution without a compound.
- An additional aim of the current invention is to disclose a method for improvement of the way a desired (and often necessary) antibacterial effect of a composition for contact lens care or eye-care/eye-drops can be reached.
- a number of peptides are naturally found in the eye. They have a protective effect on the eye and particularly the cornea.
- peptides can be used separately or in combination with other eye-care products or treatments.
- composition according to the current invention can be applied when impregnating all kinds of contact lenses, especially and preferably soft lenses, but also hard lenses, disposable lenses and long-lasting ones as well as extended wear lenses and intra-ocular lenses would benefit. Impregnation can be carried out by the user, for instance during maintenance, but also, as with new lenses, in the delivery packaging.
- a contact lens with this compound could be used when the user expects an allergic reaction, for example in a period with high levels of pollen.
- Other compounds can be used as well to either prevent or reduce allergic reactions, such as emedastine, azelastine and nedocromil.
- contact lenses according to the current invention could be found in the treatment of so-called “dry eyes” or irritated or red eyes, hence called “dry eyes.”
- dry eyes or irritated or red eyes
- eye-drops are used to treat this.
- eye-drops usually offer only short-term relief.
- the contact lenses according to the current invention offer a simple, cheap and elegant alternative.
- the compounds suggested in the current invention could be particularly advantageous to use the compounds suggested in the current invention as giving relief to dry eyes in combination with polymers from which is known or believed that they, when used in eye-drops, offer relief, such as polymers of the type polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), Carbomere or Dextrane.
- PVP polyvinylpyrrolidone
- PVA polyvinyl alcohol
- HPMC hydroxypropyl methylcellulose
- HPC hydroxy propyl cellulose
- Carbomere or Dextrane Carbomere or Dextrane.
- Other substances that may be combined with the compounds include polyhexamethylene biguanide hydrochloride (PHMB HCl), boric acid, borax, sodium chloride (NaCl), and ethylenediamine tetraacetic acid (EDTA).
- contact lenses according to the current invention can also be used to apply substances which cure or correct eye-diseases or disorders and which should be administered once or several times a day to take sufficient effect at least part of the day.
- the use of contact lenses according to the current invention could be effective here.
- the use of contact lenses will generally result in a more constant level of the effective agent at the point of application than would have been possible with the use of eye-drops or even eye-balm.
- Eye-balm also has the disadvantages of causing limited eyesight directly after application and a less easy way of application for some users compared to applying contact lenses.
- the use of the current invention with their own lenses is particularly economical, because they do not need to perform any supplementary actions.
- An advantage of the current invention is that the price of contact lenses has dropped considerably over the last few years especially that of short-term use lenses such as the so-called day-lenses, week-lenses, month-lenses or three-months'-lenses. Such lenses are a preferable embodiment of the current invention.
- compositions to be used in the procedure according to the current invention are the following:
Abstract
A contact lens kit may include one or more soft contact lenses stored in an ophthalmologically acceptable solution of hyaluronic acid or a salt of hyaluronic acid. A method of disinfecting a soft contact lens, storing a soft contact lens, or facilitating insertion of a soft contact lens in an eye, may include placing the soft contact lens into an ophthalmologically acceptable solution that comprises (a) hyaluronic acid or a salt of hyaluronic acid, and (b) at least one compound to disinfect, store, or facilitate insertion of the contact lens.
Description
- The present application is a division of U.S. application Ser. No. 10/615,592, filed Jul. 8, 2003, now U.S. Pat. No. 7,569,212, which is incorporated herein by reference and which is a continuation of International Application No. PCT/NL02/00012, filed Jan. 9, 2002, which is incorporated herein by reference and which claims the benefit of Netherlands Application No. NL1017060, filed Jan. 9, 2001.
- The current invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and/or eye-care. The invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses as well as contact lenses impregnated with the composition.
- Because they regularly have unusual objects in their eyes for years contact lens wearers have a higher chance of damaging their cornea, eye-stratum, the endothelium or other parts of the eyes than non-wearers, for example because chemical substances which may cause irritation or damage to the eye could be released from the lens or the surface of the lens after inserting the lens into the eyes. Lenses which have not been properly cleaned or damaged lenses as well as dust-particles, traces of sand or pollen which have gotten under the lens could also affect the cornea. These damages or irritations can be superficial and temporary, but could also result in far-reaching consequences since lenses are usually worn daily. Health risks could occur, varying from irritated and red eyes to serious complications such as permanent damage of the cornea resulting in blindness.
- The cause of such complications is multifarious. Placing the contact lens onto the eye disturbs its physiological condition. After habituation a new balance will be reached that can be disturbed again by various factors, such as ageing of the contact lens, damage to and deposit on the lens, change of tear-flow with respect to composition and quantity due to frequency and manner of winking, chemical toxicity of substances the user is in contact with, mechanical pressure and chronic lack of oxygen. The ageing of the user may bring about changes in his or her eyes thereby disturbing the physiological balance. The use of medication or the development of allergies may also lead to irritations or damage of parts of the eyes.
- Because nowadays contact lenses are frequently used for longer periods of time careful and regular cleaning has become more important. If this is not done sufficiently, bacteria, proteins etc., for instance, may cause irritations and damage more promptly. To prevent permanent damage it is vital that possible damage to the cornea or other parts of the eyes is treated as soon as possible.
- Moreover, contact lens wearers may need extra protection for their eyes. It could be useful to the eyes to dispense extra nutrition, such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage. In eye healthcare several products are known to assist in the accelerated recovery of the soundness of the cornea. These products, however, usually have to be administered (dripped in or applied onto the eye) separately or have to be swallowed by the user.
- It is the aim of the current invention to provide the opportunity for a long-term care or treatment and/or protection and/or care of the eyes.
- In accordance with one aspect of the present invention, a method for the production of contact lenses for the treatment and/or care and/or protection of the eye may comprise the impregnation of contact lenses in a solution which comprises one or more suitable components for the treatment and/or care and/or protection of the eye.
- In accordance with another aspect of the present invention, a composition for the treatment and/or care and/or protection of the eye may comprise at least one suitable component for the treatment and/or care and/or protection of the eye.
- In accordance with a further aspect of the present invention, a contact lens for treatment and/or care and/or protection of the eye may be impregnated with a composition comprising at least one suitable component for the treatment and/or care and/or protection of the eye.
- Considering the possibilities of irritation and damage to the cornea, the stratum, the endothelium or other parts of the eyes are manifold, one requires protection, conditioning and whenever possible, restoration of the sustained damage to the eye. The current invention therefore provides a method for the manufacture of contact lenses for the treatment and/or care and/or protection of the eyes, comprising the impregnation of contact lenses in a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes. By wearing contact lenses the compounds which treat and/or protect and/or care of the eyes will be in contact with part of the eyes. This way the lens will be a method of administering these compounds which will often imply a more long-lasting administering compared to current eye-drops. The compounds mentioned can be either absorbed into the lens material or be attached to them or both. The term “impregnate” in this application refers to either of these or to a combination of both.
- Furthermore the current invention provides a composition for the impregnation of contact lenses for the treatment and/or care and/or protection of the eyes, comprising compounds suitable for eye treatment or care or protection.
- The current invention offers various types of compounds dependent on the type of treatment, care or protection required. For the benefit of the user these compositions can be combined with the compounds usually used for disinfecting, cleaning, insertion, moisturizing, rinsing or storing of contact lenses, so that the user need not add these compounds separately. However, it is likewise possible to just impregnate the lenses with the above-mentioned care or treatment products to prevent damage caused by other cleaning-agents or disinfectants.
- Compounds that can be applied, but are not limited to substances which feed or treat the eye or may improve, accelerate or initiate local damage repair, or helps to avoid local damage or irritations of parts of the eye, are: for instance dexpanthenol, pantothenic acid, hyaluron acid, retinol (Vitamin A) and retinyl derivatives, carotene, thiamine (Vitamin B1), riboflavine (Vitamin B2), pyridoxine (Vitamin B6), nicotinic acid, nicotine acidamin, biotine (Vitamin B7), niacinamide and niacine (vitamin −B3), ascorbic acid (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatin, taurin, serine protease and other enzymes, propamidines, Vitamin D and its derivatives such as calciferol, Vitamin K, tannin, pyruates, fibroplastin, fibronectine and fibrohydrolysate, heparin, alfa-ketaglutarine acid, carnisin, laminisin, mucin, tenascin, peptides epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and all ophthalmologically acceptable salts and derivatives of the compounds mentioned above, selenium, calcium, zinc and other minerals.
- Products used for maintenance and storage of contact lenses, like cleaning products and disinfecting solutions, and sprays, so-called all-in-one solutions, storage liquids and rinsing liquids, insertion solutions and moisturizers, neutralizers in either liquid or tablet form, gels, coatings and tablets which either make or assist in making contact lens solutions or make solutions come into being or are used for or in such solutions.
- According to the current invention the composition can therefore appear in various forms, such as a solution, spray or tablet which after dissolution makes a solution. Compounds intended for the care of contact lenses may also be part of a tablet which is combined with a solution that contains the care, treatment or protection agent or the reverse. Obviously both could also be included in one tablet or in separate tablets. Even so compounds can be included in a solution that is to be mixed with a solution without a compound.
- Since the current substances which necessarily have to be applied for their germicidal and preservative effects in eye-care solutions, eye-drops and contact lens care solutions and which are germicidal in a short period of time and sufficiently limiting increase in germ population usually have the disadvantage of causing irritation or even attacking the eye to a large or lesser degree it would be greatly advantageous to use compounds in eyecare solutions, eye-drops and contact lens solutions for germicidal or conservation purposes which are non-irritant or protect against these irritations or damages. Possible damage and irritation of the cornea or other parts of the eye will thus be avoided. An additional aim of the current invention is to disclose a method for improvement of the way a desired (and often necessary) antibacterial effect of a composition for contact lens care or eye-care/eye-drops can be reached. A number of peptides are naturally found in the eye. They have a protective effect on the eye and particularly the cornea. The use of peptides in a composition for use in a contact lens solution, but also in eye-drops, could be greatly advantageous, because many peptides do not cause damage to the cornea; to some extent they also offer protection. They also offer protection from and support against bacterial infections, especially for people prone to such infections or people whose corneas are easily damaged.
- According to the current invention peptides can be used separately or in combination with other eye-care products or treatments.
- The composition according to the current invention can be applied when impregnating all kinds of contact lenses, especially and preferably soft lenses, but also hard lenses, disposable lenses and long-lasting ones as well as extended wear lenses and intra-ocular lenses would benefit. Impregnation can be carried out by the user, for instance during maintenance, but also, as with new lenses, in the delivery packaging.
- It is not necessary for the user using the contact lenses according to the current invention to be already familiar with wearing lenses. People, and even animals, who in fact do not need any eye-correction, but who require for instance certain nutrients for the eye or products to possibly initiate, support or accelerate healing sores or injuries could wear contact lenses or similar objects according to the current invention on or in the eye to facilitate the required compound(s) on or into the eye. It is not necessary for the active component with which contact lenses have been impregnated to repair or prevent any damage. Also medicines can be administered through a contact lens according to the current invention. An example of another type of effective compound, in this case a medicine, which could be administered advantageously to the eye according to the current invention is for instance cromoglycate. This compound works as a precautionary protection against allergies. A contact lens with this compound could be used when the user expects an allergic reaction, for example in a period with high levels of pollen. Other compounds can be used as well to either prevent or reduce allergic reactions, such as emedastine, azelastine and nedocromil.
- Other applications of contact lenses according to the current invention could be found in the treatment of so-called “dry eyes” or irritated or red eyes, hence called “dry eyes.” Currently mainly eye-drops are used to treat this. Such eye-drops, however, usually offer only short-term relief. In order to lengthen the availability of the active agents for the treatment of the eyes several complex or expensive possibilities for slow-release eye-drops have been proposed. The contact lenses according to the current invention offer a simple, cheap and elegant alternative.
- It could be particularly advantageous to use the compounds suggested in the current invention as giving relief to dry eyes in combination with polymers from which is known or believed that they, when used in eye-drops, offer relief, such as polymers of the type polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), Carbomere or Dextrane. Other substances that may be combined with the compounds include polyhexamethylene biguanide hydrochloride (PHMB HCl), boric acid, borax, sodium chloride (NaCl), and ethylenediamine tetraacetic acid (EDTA).
- As mentioned above contact lenses according to the current invention can also be used to apply substances which cure or correct eye-diseases or disorders and which should be administered once or several times a day to take sufficient effect at least part of the day. The use of contact lenses according to the current invention could be effective here. Moreover, the use of contact lenses will generally result in a more constant level of the effective agent at the point of application than would have been possible with the use of eye-drops or even eye-balm. Eye-balm also has the disadvantages of causing limited eyesight directly after application and a less easy way of application for some users compared to applying contact lenses. For wearers of contact lenses the use of the current invention with their own lenses is particularly economical, because they do not need to perform any supplementary actions.
- An advantage of the current invention is that the price of contact lenses has dropped considerably over the last few years especially that of short-term use lenses such as the so-called day-lenses, week-lenses, month-lenses or three-months'-lenses. Such lenses are a preferable embodiment of the current invention.
- The current invention will be illustrated in the following examples:
- Examples of compositions to be used in the procedure according to the current invention are the following:
-
- 1. PHMB HCl 2.5 ppm
- 2. Boric Acid 0.75%
- 3. Borax 0.15%
- 4. NaCl 0.40%
- 5. EDTA-Na 0.03%
- 6. HPMC 10,000 0.10%
- 7. Dexpanthenol 1.0%
- 8. pH adaptation with NaOH or HCl to pH 7.4
-
- 1. Catalase 3000 IU
- 2. KH2PO4 50 mg
- 3. K2hPO4 150 mg
- 4. NaCl q.s.
- 5. Na-EDTA 0.2 mg
- 6. Collagene 5 mg
- 7. PVP K 90 10 mg
-
- 1. HPMC 4000 cP 0.2%
- 2. Citric Acid 0.5%
- 3. Na citrate 1.0%
- 4. NaCl to 300 mOsm
- 5. Na-EDTA 0.02%
- 6. Alexidine 2 HCL 0.5 ppm
- 7. Hyaluronic Acid 0.25%
- 8. pH adaptation with NaOH or HCL ad pH 7.2
Claims (20)
1. A contact lens kit comprising one or more soft contact lenses stored in an ophthalmologically acceptable solution of hyaluronic acid or a salt of hyaluronic acid.
2. The kit of claim 1 , wherein the solution further comprises at least one compound to disinfect, store, or facilitate insertion of a soft contact lens into an eye.
3. The kit of claim 2 , wherein the at least one compound comprises at least one of polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), carbomere, and dextrane.
4. The kit of claim 1 , wherein the one or more soft contact lenses are new lenses that are stored in the solution and packaged in delivery packaging.
5. The kit of claim 1 , wherein the solution further comprises dexpanthenol.
6. The kit of claim 5 , wherein the solution comprises at least 1% dexpanthenol by weight.
7. The kit of claim 5 , wherein the soft contact lens is a day lens.
8. The kit of claim 5 , wherein the solution is an all-in-one solution.
9. The kit of claim 1 , wherein the soft contact lens is a day lens.
10. The kit of claim 1 , wherein the solution is an all-in-one solution.
11. A method of disinfecting a soft contact lens, storing a soft contact lens, or facilitating insertion of a soft contact lens in an eye, comprising placing the soft contact lens into an ophthalmologically acceptable solution that comprises (a) hyaluronic acid or a salt of hyaluronic acid, and (b) at least one compound to disinfect, store, or facilitate insertion of the contact lens.
12. The method of claim 11 wherein the solution further comprises at least one of PVP, PVA, HPMC, HPC, carbomere, and dextrane.
13. The method of claim 11 , wherein the solution comprises dexpanthenol.
14. The method of claim 13 , wherein the solution comprises at least 1% dexpanthenol by weight.
15. The method of claim 13 , wherein the soft contact lens is a day lens.
16. The method of claim 13 , wherein the solution is an all-in-one solution.
17. The method of claim 11 , wherein the soft contact lens is a day lens.
18. The method of claim 11 , wherein the solution is an all-in-one solution.
19. The method of claim 11 , wherein the soft contact lens is placed in the solution while the contact lens is not contacting an eye.
20. The method of claim 19 , wherein the soft contact lens is a new lens and is in the solution while in delivery packaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/512,521 US20090291020A1 (en) | 2001-01-09 | 2009-07-30 | Soft contact lens solution containing hyaluronic acid |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1017060 | 2001-01-09 | ||
NL1017060 | 2001-01-09 | ||
PCT/NL2002/000012 WO2002060495A1 (en) | 2001-01-09 | 2002-01-09 | Procedure and composition of treatment and/or care of the eye |
US10/615,592 US7569212B2 (en) | 2001-01-09 | 2003-07-08 | Procedure and composition of treatment and/or care of the eye |
US12/512,521 US20090291020A1 (en) | 2001-01-09 | 2009-07-30 | Soft contact lens solution containing hyaluronic acid |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/615,592 Division US7569212B2 (en) | 2001-01-09 | 2003-07-08 | Procedure and composition of treatment and/or care of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090291020A1 true US20090291020A1 (en) | 2009-11-26 |
Family
ID=19772702
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/615,592 Expired - Lifetime US7569212B2 (en) | 2001-01-09 | 2003-07-08 | Procedure and composition of treatment and/or care of the eye |
US12/512,521 Abandoned US20090291020A1 (en) | 2001-01-09 | 2009-07-30 | Soft contact lens solution containing hyaluronic acid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/615,592 Expired - Lifetime US7569212B2 (en) | 2001-01-09 | 2003-07-08 | Procedure and composition of treatment and/or care of the eye |
Country Status (14)
Country | Link |
---|---|
US (2) | US7569212B2 (en) |
EP (1) | EP1347787B2 (en) |
JP (1) | JP2004521682A (en) |
CN (1) | CN1281283C (en) |
AT (1) | ATE292985T1 (en) |
AU (1) | AU2002228449B2 (en) |
CA (1) | CA2434242A1 (en) |
DE (1) | DE60203691T3 (en) |
DK (1) | DK1347787T4 (en) |
ES (1) | ES2240710T5 (en) |
IL (2) | IL156766A0 (en) |
PL (1) | PL198969B1 (en) |
RU (1) | RU2333742C2 (en) |
WO (1) | WO2002060495A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI609957B (en) * | 2016-06-27 | 2018-01-01 | 晶碩光學股份有限公司 | Solution for treating contact lens and packaging system of contact lens |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US20070104744A1 (en) * | 2000-11-08 | 2007-05-10 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing forms of vitamin b |
AU2002228449B2 (en) | 2001-01-09 | 2007-12-06 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
MY128762A (en) * | 2001-01-12 | 2007-02-28 | Novartis Ag | Lens care product containing dexpanthenol |
DE10161110A1 (en) * | 2001-12-12 | 2003-06-26 | Ursapharm Arzneimittel Gmbh | Pharmaceutical composition for ophthalmic and rhinological use |
JP2006504701A (en) * | 2002-09-30 | 2006-02-09 | マーク・エー・バビザイェフ | Method for local treatment of eye diseases, therapeutic composition and therapeutic means thereof |
FR2849383B1 (en) * | 2002-12-26 | 2005-09-30 | Jean Noel Thorel | TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
CA2839930C (en) * | 2003-06-13 | 2016-07-05 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
US7947295B2 (en) | 2003-06-13 | 2011-05-24 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
JP4954076B2 (en) * | 2004-10-01 | 2012-06-13 | メニコン シンガポール ピーティーイー. リミテッド | Contact lens packaging container solution |
WO2006053164A2 (en) * | 2004-11-09 | 2006-05-18 | Advanced Medical Optics, Inc. | Ophthalmic solution |
US7726809B2 (en) | 2005-02-09 | 2010-06-01 | Safilens S.R.L. | Contact lens, method for producing same, and pack for storage and maintenance of a contact lens |
DE102005031361A1 (en) * | 2005-06-30 | 2007-01-04 | Biotronik Vi Patent Ag | Use of propolis as a coating material for medical implants |
DE102005055275A1 (en) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphate-free pharmaceutical composition and its use |
JPWO2007125731A1 (en) * | 2006-04-28 | 2009-09-10 | 株式会社メニコン | Soft contact lens solution, drug sustained release soft contact lens obtained using the same, and method for producing the same |
ES2624960T3 (en) * | 2006-09-29 | 2017-07-18 | Johnson & Johnson Vision Care, Inc. | Method of manufacturing ophthalmic devices used in the treatment of eye allergies |
US20080166393A1 (en) * | 2007-01-05 | 2008-07-10 | Grant Robert K | Eye Medication Delivery System |
US20090081194A1 (en) * | 2007-04-04 | 2009-03-26 | Kalsow Carolyn M | Compositions and methods for reducing risk of development, or severity, of inappropriate immune response in eyes |
WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
US20090142292A1 (en) * | 2007-12-03 | 2009-06-04 | Blackwell Richard I | Method For The Mitigation of Symptoms of Dry Eye |
US20110046033A1 (en) * | 2008-01-31 | 2011-02-24 | Jinzhong Zhang | Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function |
NL2002214C2 (en) * | 2008-11-17 | 2010-05-18 | Louis Johan Wagenaar | Contact lens care solution. |
WO2010092735A1 (en) | 2009-02-10 | 2010-08-19 | 千寿製薬株式会社 | Ring-shaped device |
CA2753106C (en) * | 2009-02-20 | 2016-09-13 | Seed Co., Ltd. | Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release |
US8440212B2 (en) * | 2009-08-24 | 2013-05-14 | Arch Chemicals, Inc. | Compositions for treating water systems |
TW201206418A (en) * | 2010-07-02 | 2012-02-16 | Holden Brien Vision Inst | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease |
IT1407283B1 (en) * | 2010-12-06 | 2014-04-04 | Paoli Ambrosi De | NEW COMPOUND OF CARNOSINE |
CA2821969A1 (en) * | 2010-12-21 | 2012-06-28 | Recopharma Ab | Tear substitutes |
TWI480039B (en) * | 2011-03-10 | 2015-04-11 | Pegavision Corp | Aqueous composition for contact lens |
CN102600050B (en) * | 2012-03-23 | 2013-05-08 | 上海暖友实业有限公司 | Eye-protecting health care patch with self-heating steam and nutrition |
PL2897604T3 (en) | 2012-09-19 | 2018-10-31 | Grespo Ab | Compositions for improvement of brain function |
CN105214071A (en) * | 2015-05-28 | 2016-01-06 | 上海昊海生物科技股份有限公司 | A kind of size variance eye drop and preparation method thereof |
WO2017030184A1 (en) * | 2015-08-20 | 2017-02-23 | 生化学工業株式会社 | Agent to be applied to ophthalmic device |
US9861940B2 (en) | 2015-08-31 | 2018-01-09 | Lg Baboh2O, Inc. | Additives for salt rejection enhancement of a membrane |
US11096391B1 (en) | 2016-01-06 | 2021-08-24 | Innovative Water Care, Llc | Polybiguanide salts in solid form for water treatment applications and kit |
US10155203B2 (en) | 2016-03-03 | 2018-12-18 | Lg Nanoh2O, Inc. | Methods of enhancing water flux of a TFC membrane using oxidizing and reducing agents |
TWI634205B (en) * | 2016-06-27 | 2018-09-01 | 晶碩光學股份有限公司 | Solution for treating contact lens |
KR101932862B1 (en) | 2017-10-30 | 2018-12-26 | 동국대학교 경주캠퍼스 산학협력단 | Compositions for Preventing and Treating Dry Eye Syndrome |
RU2679319C1 (en) * | 2018-11-27 | 2019-02-07 | Илья Александрович Марков | Gel-like artificial tears with antiseptic and reparative action |
KR102221500B1 (en) * | 2019-06-10 | 2021-03-04 | 인제대학교 산학협력단 | Method for manufacturing contact lens comprising beta-carotene for blocking blue lights |
CN114191383A (en) * | 2021-12-10 | 2022-03-18 | 江苏海伦隐形眼镜有限公司 | Contact lens nutrient solution and using method thereof |
CN114410391A (en) * | 2022-01-26 | 2022-04-29 | 深圳中科欣扬生物科技有限公司 | Contact lens care solution containing antioxidant substances and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039913A (en) * | 1998-08-27 | 2000-03-21 | Novartis Ag | Process for the manufacture of an ophthalmic molding |
US6082533A (en) * | 1998-12-15 | 2000-07-04 | Bausch & Lomb Incorporated | Contact lens package |
US6528048B1 (en) * | 1998-11-16 | 2003-03-04 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic solutions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2426757A1 (en) * | 1974-06-01 | 1975-12-11 | Norbert Armin Guenther | Contact lens made of hard or soft plastics - is impregnated with slow-release medicament for continuous eye treatment |
SU1377104A1 (en) * | 1985-07-19 | 1988-02-28 | Куйбышевский медицинский институт им.Д.И.Ульянова | Method of conducting photophoresis when curing eye diseases |
US5091421A (en) * | 1987-06-04 | 1992-02-25 | Massachusetts Institute Of Technology | Chemical prevention or reversal of cataract by phase separation inhibitors |
JP3256997B2 (en) * | 1990-08-30 | 2002-02-18 | 千寿製薬株式会社 | Stable aqueous formulation |
NZ242358A (en) * | 1991-05-10 | 1994-03-25 | Allergan Inc | Use of thiol compounds to inhibit deposits on a contact lens |
RU2055555C1 (en) * | 1992-05-07 | 1996-03-10 | Михаил Ефимович Маргус | Device for curing eye diseases |
US6106828A (en) * | 1996-02-15 | 2000-08-22 | Novo Nordisk A/S | Conjugation of polypeptides |
US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
JP4591728B2 (en) * | 1998-12-28 | 2010-12-01 | 大正製薬株式会社 | Eye drops for improving eye strain |
ES2255987T3 (en) * | 1999-03-01 | 2006-07-16 | Milcin Therapeutics Llc | OPHTHALMIC PREPARATIONS CONTAINING MUCINE. |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US8557868B2 (en) * | 2000-11-04 | 2013-10-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions using low molecular weight amines |
AU2002239545B2 (en) † | 2000-11-08 | 2006-10-05 | Fxs Ventures, Llc | Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
AU2002228449B2 (en) | 2001-01-09 | 2007-12-06 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
MY128762A (en) * | 2001-01-12 | 2007-02-28 | Novartis Ag | Lens care product containing dexpanthenol |
-
2002
- 2002-01-09 AU AU2002228449A patent/AU2002228449B2/en not_active Ceased
- 2002-01-09 CA CA002434242A patent/CA2434242A1/en not_active Abandoned
- 2002-01-09 ES ES02710528T patent/ES2240710T5/en not_active Expired - Lifetime
- 2002-01-09 IL IL15676602A patent/IL156766A0/en unknown
- 2002-01-09 JP JP2002560686A patent/JP2004521682A/en active Pending
- 2002-01-09 EP EP02710528A patent/EP1347787B2/en not_active Expired - Lifetime
- 2002-01-09 DK DK02710528.7T patent/DK1347787T4/en active
- 2002-01-09 DE DE60203691T patent/DE60203691T3/en not_active Expired - Lifetime
- 2002-01-09 WO PCT/NL2002/000012 patent/WO2002060495A1/en active IP Right Grant
- 2002-01-09 RU RU2003124644/15A patent/RU2333742C2/en not_active IP Right Cessation
- 2002-01-09 AT AT02710528T patent/ATE292985T1/en active
- 2002-01-09 PL PL362746A patent/PL198969B1/en unknown
- 2002-01-09 CN CNB028043340A patent/CN1281283C/en not_active Expired - Fee Related
-
2003
- 2003-07-03 IL IL156766A patent/IL156766A/en not_active IP Right Cessation
- 2003-07-08 US US10/615,592 patent/US7569212B2/en not_active Expired - Lifetime
-
2009
- 2009-07-30 US US12/512,521 patent/US20090291020A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039913A (en) * | 1998-08-27 | 2000-03-21 | Novartis Ag | Process for the manufacture of an ophthalmic molding |
US6528048B1 (en) * | 1998-11-16 | 2003-03-04 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic solutions |
US6082533A (en) * | 1998-12-15 | 2000-07-04 | Bausch & Lomb Incorporated | Contact lens package |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI609957B (en) * | 2016-06-27 | 2018-01-01 | 晶碩光學股份有限公司 | Solution for treating contact lens and packaging system of contact lens |
US10918761B2 (en) | 2016-06-27 | 2021-02-16 | Pegavision Corporation | Solution for treating contact lens and contact lens packaging system |
Also Published As
Publication number | Publication date |
---|---|
AU2002228449B2 (en) | 2007-12-06 |
ES2240710T5 (en) | 2011-02-08 |
US20040057980A1 (en) | 2004-03-25 |
CA2434242A1 (en) | 2002-08-08 |
RU2003124644A (en) | 2005-01-10 |
DE60203691T3 (en) | 2011-08-18 |
CN1489480A (en) | 2004-04-14 |
EP1347787B2 (en) | 2010-09-08 |
DK1347787T3 (en) | 2005-08-08 |
PL362746A1 (en) | 2004-11-02 |
US7569212B2 (en) | 2009-08-04 |
EP1347787B1 (en) | 2005-04-13 |
PL198969B1 (en) | 2008-08-29 |
IL156766A (en) | 2009-05-04 |
CN1281283C (en) | 2006-10-25 |
JP2004521682A (en) | 2004-07-22 |
DE60203691D1 (en) | 2005-05-19 |
WO2002060495A1 (en) | 2002-08-08 |
EP1347787A1 (en) | 2003-10-01 |
IL156766A0 (en) | 2004-02-08 |
ATE292985T1 (en) | 2005-04-15 |
RU2333742C2 (en) | 2008-09-20 |
ES2240710T3 (en) | 2005-10-16 |
DK1347787T4 (en) | 2011-01-03 |
DE60203691T2 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7569212B2 (en) | Procedure and composition of treatment and/or care of the eye | |
AU2002228449A1 (en) | Procedure and composition of treatment and/or care of the eye | |
ES2374607T3 (en) | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid. | |
US6024954A (en) | Compositions and methods for disinfecting contact lenses and preserving contact lens care products | |
NL2002214C2 (en) | Contact lens care solution. | |
JP2014028857A (en) | Chlorous acid compound-containing aqueous composition containing menthol | |
KR100348237B1 (en) | One-component combination preparation, disinfection, neutralization and cleaning methods for disinfecting, neutralizing and cleaning contact lenses | |
JP5686454B1 (en) | Contact lens mounting liquid and method for improving refractive index of contact lens using the same | |
AU5454594A (en) | Ophthalmic solution and method of use | |
JP6615548B2 (en) | Ophthalmic composition | |
JP2009175731A (en) | Chlorous acids compound-containing water-based composition containing glycerol and phosphoric acid compound | |
JP2009199074A (en) | Aqueous composition containing chlorous acid compound containing polyoxyethylene castor oil derivative and phosphoric acid compound | |
EP1522321B1 (en) | Method for disinfecting and/or cleaning contact lenses, using a liquid aqueous composition comprising at least one constituent of the aloe vera plant | |
JP4817621B2 (en) | Contact lens care method and composition | |
JP2006000170A (en) | Contact lens composition | |
JP2007513951A (en) | Use of organic buffers to enhance the antimicrobial activity of pharmaceutical compositions | |
EP2642333B1 (en) | Soft contact lens application method | |
Lyle et al. | Constituents of Ophthalmic Preparations | |
JP2016183186A (en) | Ophthalmic composition | |
WO2004082673A1 (en) | Liquid ophthalmic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |